Pediatrics

From newsworthy moments to groundbreaking research, these were the most-read pediatrics-related articles on Pharmacy Times in 2023.

This approval makes birch triterpenes the first treatment for wounds associated with junctional epidermolysis bullosa to be approved by the FDA.

The researchers emphasized that individuals must advocate for new policies that could aid regulation of harmful information being shared through social media platforms.

This is the first FDA approval for a therapy intended to reduce the risk of relapse in patients with high-risk neuroblastoma.

Out of the 600 infants, 169 were born prematurely, 487 did not have underlying medical conditions, and 143 had to receive invasive mechanical ventilation.

Bivigam was initially approved by the FDA in May 2019 for the treatment of primary humoral immunodeficiency, including a group of genetic disorders.

The results found that 93% of individuals in the high-risk group presented persistently positive antiphospholipid antibodies, compared with 47% of individuals in the lower-risk group.

The approval marks isavuconazonium sulfate as the only granted azole antifungal therapy for pediatric patients with invasive aspergillosia and invasive mucormycotic who are as young as age 1.

An animal study shows that early-life stress may increase risk-taking behaviors in adulthood; in humans, this could translate to risk of substance use disorder.

There is a great need to protect families and children that are commercially insured following the COVID-19 pandemic.

Pediatric individuals that are higher risk for APS must be followed to better understand affects

The growth chart could be a fast and accessible resource to indicate lean muscle mass in children.

Additionally, infants that were less than 3 months and born prematurely were more at risk of intubation when in the intensive care unit for respiratory syncytial virus.

Additional doses for the prophylaxis of respiratory syncytial virus will immediately be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program.

It will be interesting to see RSV hospitalization rates over this upcoming season following the rollout of RSV vaccines and monoclonal antibody administration.

The genes that predispose a person to sleep problems can impact that person across their entire lifetime, so interventions targeted toward a younger audience could be beneficial.

The on-demand enzyme replacement therapy reduced acute thrombotic thrombocytopenic purpura events in patients who experience potentially fatal blood clotting.

Socioeconomic, racial, and insurance disparities impact individuals' health before and after receiving surgery to treat adolescent idiopathic scoliosis.

It's key for clinicians to optimize therapy prior to systemic agents.

Infants younger than 6 months old are the highest risk for severe RSV infection, so researchers aim to target this group for prevention methods

Children with a score of higher than 30 on the CHALF Score scale will need an emergency transplant.

The approval is supported by safety data from clinical trials assessing abatacept in the treatment of patients aged 2 to 17 with psoriatic arthritis.

Vosoritide is a daily injection for children with achondroplasia who have open epiphyses, given under the skin and administered by a caregiver.

Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.

In a recent study, approximately 99% of children who received solid organ transplant and live vaccination against rubella had antibodies 1 to 3 months post-vaccination.